Local health provider claims good results with at-home COVID-19 treatment

Local Doctor Offers Controversial Covid19 Regiment

FORT SCOTT, Kan. – In a small family practice in southeast Kansas, a healthcare provider claims to have found a better way.

“I’ve seen probably close to 50 at this point. Small sample around here,” says Ryan Lewis, a nurse practitioner at Fort Scott Family Medicine.

Lewis spends his time divided between the military and being a nurse practitioner at the clinic in Fort Scott. He says his military background drove him to find a way to save more lives, especially as nationally authorized treatment options for COVID-19 are slow to come out.

“I’m not a put myself out there type of person. But when family or friends or people you know die, and it seems like there’s nothing to be done, well,” says Lewis.

So after reading studies done on several potential treatments for the virus — he now claims to have found an effective regimen for treating COVID-19 symptoms at home.

“A lot of this at first came from Dr. Peter McCullough down in Texas,” says Lewis.

When a patient tells him they have tested positive, he does a couple of things. If their symptoms are mild, he tells them to take Famotidine (an over-the-counter antihistamine and antacid), Vitamin C, Vitamin D3, Zinc, Quercetin, Aspirin, and Berberine.

For moderate symptoms, he has them take the previously mentioned supplements and medications but adds Zpack, Dexamethasone, Hydroxychloroquine, Ivermectin, and Fluvoxamine.

For severe cases, he adds a nebulizer treatment and/or supplemental oxygen if it’s needed.

Covid Treatment Protocol

Lewis explains that over the last few months, all but a few of the roughly 50 patients he’s treated this way have had good outcomes.

“Only one has been hospitalized, two had to go to the ER for more invasive.. they weren’t vented, but I believe they gave them Remdisivir,” says Lewis. “That’s it. Everybody else has had a complete and full recovery.”

But, several pieces of the protocol are not backed up by the nation’s top disease experts. The National Institutes of Health say there’s not enough data to recommend for or against vitamin C, D3, or Zinc for Covid treatment or prevention. Several of the other medications are the same — with studies ongoing, but more evidence being needed before recommendations are made. However, there are two medications the FDA actively warns against using. The FDA says Ivermectin can interact negatively with other medications, like blood thinners. The biggest danger with Ivermectin comes when large doses are administered, like what is found in farm supply stores.

The FDA also cautions against using hydroxychloroquine, stating it can cause serious heart rhythm problems and other safety issues. The Emergency Use Authorization for hydroxychloroquine was revoked by the FDA in June because “These medicines showed no benefit for decreasing the likelihood of death or speeding recovery.”

“From what I have seen, I can’t argue with the results. From what I hear from other providers that have done the same thing with a much larger patient base and had the same results… I can’t argue with that,” explains Lewis. “So, yeah, they say that, but then we also have a brain that we can use and go from there. I looked at all the counter-arguments. I’m very confident at this point… it’s at least something, as opposed to nothing.”

The FDA has authorized the use of Remdisivir and monoclonal antibodies for the treatment of COVID-19. And recently the FDA gave full authorization to Pfizer’s COVID-19 vaccine for people 16 and older.

Breakdown of each piece of the protocol, and what is being said about them.

Vitamin C: The NIH states, “There is insufficient evidence for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of vitamin C for the treatment of COVID-19 in non-critically ill patients… and critically ill patients.”

Vitamin D3: The NIH states, “There is insufficient evidence to recommend either for or against the use of vitamin D for the prevention or treatment of COVID-19.”

Zinc: The NIH states, “There is insufficient evidence for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of zinc for the treatment of COVID-19. The Panel recommends against using zinc supplementation above the recommended dietary allowance for the prevention of COVID-19, except in a clinical trial.” According to the FDA, the recommended dietary daily allowance for zinc supplementation is 11 mg for adults and children aged 4 years and older.

Aspirin: A study published on the NIH website states, “The authors recommend a low-dose aspirin regimen for primary prevention of arterial thromboembolism in patients aged 40-70 years who are at high atherosclerotic cardiovascular disease risk, or an intermediate risk with a risk-enhancer and have a low risk of bleeding. Aspirin’s protective roles in COVID-19 associated with acute lung injury, vascular thrombosis without previous cardiovascular disease and mortality need further randomized controlled trials to establish causal conclusions.”

Famotidine: A study published on the NIH website states, “There was no association between incidence of COVID-19 and use of reflux medications, including famotidine at doses used orally to manage reflux and high dose PPIs. Reflux medications did not protect against or increase the risk of COVID-19.”

Berberine: A study published on the NIH website states, “As an ingredient recommended in guidelines issued by the China National Health Commission for COVID-19 to be combined with other therapy, berberine is a promising orally administered therapeutic candidate against SARS-CoV and SARS-CoV-2.”

Quercetin: A study published in the US National Library of Medicine states, “According to the results obtained both in vitro and in vivo, good perspectives have been opened for quercetin. Nevertheless, further studies are needed to better characterize the mechanisms of action underlying the beneficial effects of quercetin on inflammation and immunity.”

Zpack (AKA Azithromycin). A study published in The Journal of the American Medical Association states, “Among outpatients with SARS-CoV-2 infection, treatment with a single dose of azithromycin compared with placebo did not result in greater likelihood of being symptom free at day 14. These findings do not support the routine use of azithromycin for outpatient SARS-CoV-2 infection.”

Dexamethasone: The NIH has recommended the use of Dexamethasone, “In hospitalized patients with COVID-19 who require invasive mechanical ventilation or ECMO,” and, “The Panel recommends the use of dexamethasone plus tocilizumab for patients who are within 24 hours of admission to the ICU.” A study in the New England Journal of Medicine also states, “Our results show that among hospitalized patients with Covid-19, the use of dexamethasone for up to 10 days resulted in lower 28-day mortality than usual care in patients who were receiving invasive mechanical ventilation at randomization.”

Hydroxychloroquine: The FDA actively cautions against using Hydroxychloroquine to treat COVID-19, reporting heart rhythm problems and other serious issues.

Ivermectin: The FDA actively cautions against using Ivermectin, stating, “Even the levels of ivermectin for approved uses can interact with other medications, like blood-thinners. You can also overdose on ivermectin, which can cause nausea, vomiting, diarrhea, hypotension (low blood pressure), allergic reactions (itching and hives), dizziness, ataxia (problems with balance), seizures, coma and even death.”

Fluvoxamine: Fluvoxamine is a selective serotonin reuptake inhibitor, approved by the FDA as a treatment for OCD, depression and other diseases. The NIH states, “Fluvoxamine is not FDA-approved for the treatment of any infection.”